Cumberland Partners Ltd Purchases 4,126 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Cumberland Partners Ltd boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 9.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,326 shares of the pharmaceutical company's stock after purchasing an additional 4,126 shares during the period. Vertex Pharmaceuticals comprises approximately 1.3% of Cumberland Partners Ltd's holdings, making the stock its 22nd largest position. Cumberland Partners Ltd's holdings in Vertex Pharmaceuticals were worth $19,058,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Northwest Investment Counselors LLC acquired a new position in Vertex Pharmaceuticals during the third quarter worth $25,000. Dunhill Financial LLC increased its stake in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 24 shares in the last quarter. Highline Wealth Partners LLC purchased a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at $33,000. Finally, Brown Lisle Cummings Inc. acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter worth $30,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX traded up $3.94 during trading on Friday, reaching $484.27. 793,579 shares of the company's stock traded hands, compared to its average volume of 1,520,611. The stock has a market capitalization of $124.35 billion, a P/E ratio of -220.04, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a 50 day moving average of $435.64 and a 200-day moving average of $460.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.58 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on VRTX. BMO Capital Markets dropped their price objective on Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating for the company in a research report on Friday, December 20th. Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price target for the company. in a report on Thursday, January 30th. Cantor Fitzgerald restated an "overweight" rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Morgan Stanley boosted their price target on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an "equal weight" rating in a report on Tuesday, February 11th. Finally, Barclays upped their target price on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 11th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $505.61.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the sale, the executive vice president now owns 67,695 shares in the company, valued at approximately $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.